Preclinical synergistic effects when combining a radiolabelled HER2-targeting single domain antibody with PARP inhibitor Olaparib

Abstract Background The HER2 targeted therapy paradigm has increasingly shifted in recent years from focussed treatment of only cancers with high HER2 expression towards those with also low HER2 expression, unlocking a larger subset of patients, in either single or combination treatment strategies....

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Jonatan Dewulf, Laurent Navarro, Nina Dumauthioz, Marion Berdal, Surasa Nagachinta, Vaiva Gaspariunaite, Ana Rita Pombo Antunes, Tony Lahoutte, Sam Massa, Nick Devoogdt, Matthias D’Huyvetter
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	BMC 2025-12-01
Цуврал:	Journal of Translational Medicine
Нөхцлүүд:	Single domain antibodies Radioligand therapy HER2 Oncology
Онлайн хандалт:	https://doi.org/10.1186/s12967-025-07572-2
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!